These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32277577)

  • 1. PASylation Enhances the Stability, Potency, and Plasma Half-Life of Interferon α-2a: A Molecular Dynamics Simulation.
    Shamloo A; Rostami P; Mahmoudi A
    Biotechnol J; 2020 Aug; 15(8):e1900385. PubMed ID: 32277577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins.
    Schlapschy M; Binder U; Börger C; Theobald I; Wachinger K; Kisling S; Haller D; Skerra A
    Protein Eng Des Sel; 2013 Aug; 26(8):489-501. PubMed ID: 23754528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of Certolizumab Fab' properties by PASylation technology.
    Mazaheri S; Talebkhan Y; Mahboudi F; Nematollahi L; Cohan RA; Mirabzadeh Ardakani E; Bayat E; Sabzalinejad M; Sardari S; Torkashvand F
    Sci Rep; 2020 Oct; 10(1):18464. PubMed ID: 33116155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action.
    Gebauer M; Skerra A
    Bioorg Med Chem; 2018 Jun; 26(10):2882-2887. PubMed ID: 29102080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals.
    Ahmadpour S; Hosseinimehr SJ
    Curr Drug Deliv; 2018; 15(3):331-341. PubMed ID: 29165076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PASylation technology improves recombinant interferon-β1b solubility, stability, and biological activity.
    Zvonova EA; Ershov AV; Ershova OA; Sudomoina MA; Degterev MB; Poroshin GN; Eremeev AV; Karpov AP; Vishnevsky AY; Goldenkova-Pavlova IV; Petrov AV; Ruchko SV; Shuster AM
    Appl Microbiol Biotechnol; 2017 Mar; 101(5):1975-1987. PubMed ID: 27833991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Design, Expression and Evaluation of PASylated Human Recombinant Erythropoietin with Enhanced Functional Properties.
    Hedayati MH; Norouzian D; Aminian M; Teimourian S; Ahangari Cohan R; Sardari S; Khorramizadeh MR
    Protein J; 2017 Feb; 36(1):36-48. PubMed ID: 28168382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PASylated interferon α efficiently suppresses hepatitis B virus and induces anti-HBs seroconversion in HBV-transgenic mice.
    Xia Y; Schlapschy M; Morath V; Roeder N; Vogt EI; Stadler D; Cheng X; Dittmer U; Sutter K; Heikenwalder M; Skerra A; Protzer U
    Antiviral Res; 2019 Jan; 161():134-143. PubMed ID: 30439382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PASylation improves pharmacokinetic of liposomes and attenuates anti-PEG IgM production: An alternative to PEGylation.
    Zhang Q; Li S; Wu W; Xia X; Zhang J
    Nanomedicine; 2023 Jan; 47():102622. PubMed ID: 36280044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How PEGylation enhances the stability and potency of insulin: a molecular dynamics simulation.
    Yang C; Lu D; Liu Z
    Biochemistry; 2011 Apr; 50(13):2585-93. PubMed ID: 21332191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PASylated Urate Oxidase Enzyme: Enhancing Biocatalytic Activity, Physicochemical Properties, and Plasma Half-Life.
    Najjari A; Shahbazmohammadi H; Nojoumi SA; Omidinia E
    ACS Omega; 2022 Dec; 7(50):46118-46130. PubMed ID: 36570261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technology.
    Aghaabdollahian S; Ahangari Cohan R; Norouzian D; Davami F; Asadi Karam MR; Torkashvand F; Vaseghi G; Moazzami R; Latif Dizaji S
    Sci Rep; 2019 Feb; 9(1):2978. PubMed ID: 30814652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational Approach for Rational Design of Fusion Uricase with PAS Sequences.
    Najjari A; Rahimi H; Nojoumi SA; Omidinia E
    Int J Mol Cell Med; 2020; 9(1):90-103. PubMed ID: 32832488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PASylation of Murine Leptin Leads to Extended Plasma Half-Life and Enhanced in Vivo Efficacy.
    Morath V; Bolze F; Schlapschy M; Schneider S; Sedlmayer F; Seyfarth K; Klingenspor M; Skerra A
    Mol Pharm; 2015 May; 12(5):1431-42. PubMed ID: 25811325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The polypeptide biophysics of proline/alanine-rich sequences (PAS): Recombinant biopolymers with PEG-like properties.
    Breibeck J; Skerra A
    Biopolymers; 2018 Jan; 109(1):. PubMed ID: 29076532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the interaction between a novel, protein-stabilizing dipeptide and Interferon-alpha-2a by construction of a Markov state model from molecular dynamics simulations.
    Tosstorff A; Peters GHJ; Winter G
    Eur J Pharm Biopharm; 2020 Apr; 149():105-112. PubMed ID: 32035237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Site-specific monoPEGylated interferon alpha2a mediated by microbial transglutaminase].
    Hui X; Cao W; Zhang D; Ge W; Li S; Li Y
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):750-762. PubMed ID: 32347069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Proline, Alanine, Serine Repeat Sequence for Pharmacokinetic Enhancement of Anti-VEGF Single-Domain Antibody.
    Khodabakhsh F; Salimian M; Mehdizadeh A; Khosravy MS; Vafabakhsh A; Karami E; Cohan RA
    J Pharmacol Exp Ther; 2020 Oct; 375(1):69-75. PubMed ID: 32669367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
    Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life.
    Brandl F; Busslinger S; Zangemeister-Wittke U; Plückthun A
    J Control Release; 2020 Nov; 327():186-197. PubMed ID: 32768630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.